Samsung Bioepis confirms it filed biosimilar Enbrel in EU
This article was originally published in Scrip
Executive Summary
Samsung Bioepis has confirmed that it filed the biosimilar version of Amgen's TNF-inhibitor Enbrel (etanercept) that is now being assessed by the European Medicines Agency's scientific committee, the CHMP.